MRD response. (A) MRD levels before treatment and after the first 3 courses of venetoclax combinations, expressed as NPM1 copies per 10⁵ABL in bone marrow. (B) Response rates in the whole cohort and depending on type of molecular failure, FLT3-ITD status at diagnosis and type of low-intensity chemotherapy given with venetoclax.